International Journal of Current Research in Physiology and Pharmacology (IJCRPP) https://sumathipublications.com/index.php/ijcrpp <p><strong>eISSN: 2523-6709,&nbsp;</strong><strong>pISSN: 2523-6695.</strong></p> <p style="text-align: left;">(Logos are embedded with links)</p> <hr> <p style="text-align: left;"><a href="https://www.base-search.net/Search/Results?q=dccoll:ftsumathipubl&amp;refid=dcrecen" target="_blank" rel="noopener"><img src="/public/site/images/admin/base.png" alt=""></a> <a href="https://search.crossref.org/?q=+2521-0394&amp;publication=International+Journal+of+Clinical+and+Biomedical+Research&amp;publisher_str=Sumathi+Publications&amp;type=Journal+Article" target="_blank" rel="noopener"><img src="/public/site/images/admin/crossref1.png" alt=""></a> <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=2523-6695&amp;btnG=" target="_blank" rel="noopener"><img src="/public/site/images/admin/GoogleScholar1.png" alt=""></a> <a href="https://www.worldcat.org/search?q=ijcrpp&amp;qt=results_page" target="_blank" rel="noopener"><img src="/public/site/images/admin/logo_wcmasthead_en1.png" alt=""></a> <a href="http://index.pkp.sfu.ca/index.php/browse/archiveInfo/4036" target="_blank" rel="noopener"><img src="/public/site/images/admin/pkp-index-301.png" alt=""></a> <a href="http://www.sherpa.ac.uk/romeo/search.php?issn=2523-6695&amp;la=en" target="_blank" rel="noopener"><img src="/public/site/images/admin/sherparomeo-home.jpg" alt=""></a></p> <hr> <p>International Journal of Current Research in Physiology and Pharmacology (IJCRPP) provides an outlet for research scientists in areas of Health Sciences. IJCRPP is open access, online &amp; Print, peer-reviewed international journal with a primary objective to provide research and applications related to Physiology, Pharmacology and Clinical Medicine.</p> <p>Submitted papers must be in technical English, suitable for scientific publication. All articles have to be original articles that have not been published elsewhere or are being considered for publication in other journals. All articles submitted will be peer-reviewed by experts. Receipt of the manuscript will be acknowledged by email. Every effort will be made to complete the review process within 3 weeks and communicated to the corresponding author. Papers should be submitted electronically on the journal's website. The Editorial Board will strive for the quality of the journal and will also index the journal in various indexing bodies and the information will be updated on the journal website from time to time.</p> <p>We welcome all your submissions.</p> <p>I hope you will consider IJCRPP for your next submission.</p> <p>If any further information is required please mail to:</p> <p><a href="mailto:journaloffice@littlebaypublishers.com" target="_blank" rel="noopener">editor@sumathipublications.com</a> or</p> <p><a href="mailto:editor.ijcrpp@gmail.com" target="_blank" rel="noopener">editor.ijcrpp@gmail.com</a>.</p> <p>The journal accepts manuscripts in the following forms:</p> <ul> <li class="show">Original research articles</li> <li class="show">Reviews</li> <li class="show">Case reports</li> <li class="show">Short communications</li> <li class="show">Letters to editor</li> <li class="show">Discussion papers</li> <li class="show">Clinical Experience</li> <li class="show">Clinicopathological correlation</li> <li class="show">Book reviews</li> <li class="show">"How to do it" type articles describing new methods or procedures.</li> </ul> <p>Aim :</p> <ul> <li class="show">Our goal is to stimulate new research ideas and foster practical application from the research findings. The journal publishes original research, review articles, case reports of such high quality as to attract contributions from the relevant international communities.</li> </ul> <p>Critical Objective:</p> <ol> <li class="show">To maintain the highest standards of editorial integrity</li> <li class="show">To improve health, health care, and health education, internationally by elevating the quality of medical care, disease prevention, and research</li> <li class="show">To publish original, important, well-documented, peer-reviewed articles on basic medical sciences subject topics</li> <li class="show">To provide doctors with continuing education in basic&nbsp; science to support clinical decisions</li> <li class="show">To enable physicians to remain informed in multiple areas of basic medical science, including developments In the field of health education.</li> <li class="show">To achieve the highest level of ethical medical journalism and to produce a publication that is timely, credible, and enjoyable to read.</li> </ol> <p>Kind Regards,</p> <p>IJCRPP Editorial Team.</p> en-US <p>The journal <strong>allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions</strong>.</p> <p>The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.</p> <p><strong>What are my rights as an author?</strong><br>It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as<br>Author. Journal's standard policies allow the following re-use rights:</p> <ul> <li class="show">The journal allows the author(s) to hold the copyright without restrictions.</li> <li class="show">The journal allows the author(s) to obtain publishing rights without restrictions.</li> <li class="show">You may do whatever you wish with the version of the article you submitted to the journal.</li> <li class="show">Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.</li> <li class="show">You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.</li> <li class="show">You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.</li> </ul> editor@sumathipublications.com (IJCRPP, Sumathi Publications) journaloffice@sumathipublications.com (Journal office) Thu, 25 Apr 2019 02:22:51 +0000 OJS 3.1.1.4 http://blogs.law.harvard.edu/tech/rss 60 Competency based undergraduate curriculum in Pharmacology for the Indian medical graduate: Challenges in assessment. https://sumathipublications.com/index.php/ijcrpp/article/view/265 Naser Ashraf Tadvi, Mohammed Rehan Asad ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc-sa/4.0 https://sumathipublications.com/index.php/ijcrpp/article/view/265 Sun, 21 Apr 2019 00:34:57 +0000 Effects of alpha, beta momorcharin fruit extract with the combination of paclitaxel in the treatment of glioma cancer in-vivo. https://sumathipublications.com/index.php/ijcrpp/article/view/269 <p>The vegetable <em>Momordica charantia </em>L., (family: Cucurbitaceae) is a scientific name of the plant and its fruit. It is also known by other names, for instance in the USA it is known as Bitter gourd or balsam pear while its referred to as the African cucumber in many African countries. &nbsp;<em>M.charantia</em>is believed to posse’s anti-carcinogenic properties and it can modulate its effect via xenobiotic metabolism and oxidative stress. This study was specifically designed to investigate the cellular mechanisms whereby α, β momorcharin an extract of <em>M. charantia</em>can induce cell death with the combination of paclitaxel.&nbsp; Different concentration (200µM - 1000µM)of the α, β momorcharin fruit extract were treated (24 hrs incubation) separately with three different cancer cell lines 1321N1, Gos-3, U87-MG and normal L6 muscle cell line. The results also show that paclitaxel(250 µg) with (1000 µM) of the α, β momorcharinextract of <em>M. Charantia,</em>and result in significant decreases in cell viability for each cell line, these effects were additive compared to the individual effect of paclitaxel. &nbsp;</p> <p><strong>&nbsp;</strong></p> GUNASEKAR MANOHARAN ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc-sa/4.0 https://sumathipublications.com/index.php/ijcrpp/article/view/269 Sun, 21 Apr 2019 00:00:00 +0000 EFFECT OF AFLATOXIN M1, "A HYDROXYLATED METABOLITE OF B1" ON SPERM CELL QUALITY OF ADULT MALE WISTAR RATS. https://sumathipublications.com/index.php/ijcrpp/article/view/250 <p>The effect of aflatoxin on reproductive health takes a systematic approach as it indicates that a significant number of people living in the third world regions are exposed to these toxins due to the poor storage of grains. To expose the effects of aflatoxin M1 a hydroxylated metabolite of aflatoxin M1 Twenty four Adult male Wister rats were acclimatized and broken down into four groups, Test Group one (Two weeks exposure), Group Two ( four weeks exposure), Group Three ( Six weeks exposure) and Group Four ( Control Group). The Test Group 1, 2 and 3 were orally administered 7.2g/kg (LD50) of Aflatoxin M1 for the desired weeks of exposure and the sperm cell quality was assessed to determine the effect of Aflatoxin M1 on sperm cell quality in Adult male wister rat. The predetermined level of sperm cell quality is its ability to be motile as the motility of the sperm cell determines its viability. Group three had the highest presence of sluggishly immotile cells with very low progressive motility, followed by group, two and one, 37.5+ 9.97, 55.00+9.91, and 71.67+3.07 as against the control groups 85.8+2.17 with the highest significance at the group three which showed an extended exposure of aflatoxin m1 (p=0.05). This study links infertility and aflatoxin consumption, as the higher the doses the more spermatotoxicity is built which invariably could lead to sterility and azoospermia.</p> Ibeh Isaiah Nnanna, Taidi Ekrakene, Okungbowa MO, Otabor Florence, Omorodion Nosa Terry ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc-sa/4.0 https://sumathipublications.com/index.php/ijcrpp/article/view/250 Thu, 25 Apr 2019 00:00:00 +0000